Arikace: Phase III data

The open-label, European and Canadian Phase III CLEAR-108 trial in 302 CF patients with chronic P. aeruginosa infection showed that once-daily 560 mg Arikace met the primary endpoint of non-inferiority to twice-daily 300 mg TOBI tobramycin inhalation solution in the mean